Tennessee
(State
or Other Jurisdiction
of
Incorporation)
|
0--24425
(Commission
File Number) |
54-1684963
(IRS
Employer
Identification
No.) |
¨ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
¨ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
¨ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
¨ |
Pre-commencement
communications pursuant to Rule 13e-2(b) under the Exchange Act (17
CFR 240.13e-4(c)) |
Exhibit
No. |
Exhibit |
10.1 |
Termination
Agreement, dated as of February 27, 2005, by and among Mylan, Summit and
King |
99.1 |
Joint
Press Release of Mylan and King, dated February 27,
2005 |
KING
PHARMACEUTICALS, INC.,
| |
By | |
/s/
Brian A. Markison | |
Name: Brian
A. Markison | |
Title: President
and Chief Executive Officer |
Exhibit
No. |
Exhibit |
10.1 |
Termination
Agreement, dated as of February 27, 2005, by and among Mylan, Summit and
King |
99.1 |
Joint
Press Release of Mylan and King, dated February 27,
2005 |